... of this study was limited to 4 weeks; further research is required to evaluate the long-term safety and efficacy of treatment with fesoterodine plus tamsulosin in men with persistent bothersome OAB symptoms despite α-blocker therapy. In conclusion, the results suggest that the men who fitted the inclusion...

...Hiromitsu Mimata; Fuminori Satoh; Hitoshi Ohno; Midori Miyoshi; Yoshio Nomura Background: Currently, α-blocker is becoming first-line drug therapy for benign prostatic hyperplasia (BPH). Although highly effective results are obtained with this therapy, a difference between the objective...